The orally administered gepotidacin is a member of a novel class of type IIA topoisomerase inhibitors , also called novel bacterial topoisomerase inhibitors ( NBTIs ), for which the mode of action and binding mode with a topoisomerase was first disclosed in 2010 by [...]
4 minute read
May 31, 2023
Gepotidacin: A Potential First-In-Class Oral Antibiotic With Recent Positive Ph. III Data
gepotidacin
oral BID antibacterial Type II topoisomerase inhibitor Ph. III for uncomplicated UTIs from unbiased antibacterial screen + opt. ECCMID, April 2023 Glaxo (GSK), Stevenage, UK
Loading...
